Abstract
High-melting-point active pharmaceutical ingredients (APIs) frequently undergo amorphization during hot-melt extrusion (HME) through progressive dissolution and incorporation in a softened polymer rather than by direct melting. The kinetics of this process are strongly influenced by particle size, yet rapid experimental methods for evaluating particle dissolution behaviour in the softened polymer prior to extrusion remain limited. In this work, a quantitative hot-stage microscopy (HSM)-based workflow combined with image analysis was developed to evaluate particle-size-dependent dissolution of a model high-melting-point API into softened Kollidon® VA 64 under predefined thermal conditions. The dissolved fraction of individual particle-size classes was quantified throughout the experiment to determine the particle-size range associated with complete and incomplete dissolution. Complete dissolution was consistently observed for particles smaller than approximately 15–20 μm, whereas particles exceeding approximately 40 μm exhibited a markedly increased probability of retaining residual drug particle under the applied conditions. Between these limits, the dissolved fraction decreased progressively with increasing particle size. Because the methodology evaluates particle dissolution under static thermal conditions, the identified particle-size limits should be regarded as conservative, formulation-specific estimates rather than universal HME processing limits. The proposed workflow transforms HSM from a primarily qualitative visualization technique into a quantitative preformulation screening tool that enables rapid evaluation of particle-size-related processing risks while requiring only minimal quantities of material.
Introduction
Poor aqueous solubility remains one of the major challenges in pharmaceutical development, limiting the oral bioavailability of a substantial proportion of newly discovered drug candidates [1, 2]. Among the available formulation strategies, amorphous solid dispersions (ASDs) have become one of the most successful approaches for improving the dissolution performance of poorly water-soluble active pharmaceutical ingredients (APIs) [2, 3]. In ASDs, the API is molecularly dispersed within an amorphous polymeric carrier, thereby increasing the saturation solubility and dissolution rate while reducing the energetic barrier associated with crystal lattice disruption [2, 4,5,6]. The polymer matrix further stabilizes the amorphous drug by restricting molecular mobility and suppressing recrystallization through steric hindrance and intermolecular interactions [2, 6,7,8]. Consequently, ASDs have become an established platform for improving the oral delivery of poorly soluble drugs [2, 3].
Several manufacturing techniques have been developed for ASD preparation, including solvent evaporation methods, melt-based techniques, ball milling, spray-drying, electrospinning, co-precipitation, supercritical fluid methods, lyophilization, and hot-melt extrusion (HME) [9,10,11,12,13,14,15,16,17]. Among these, HME has attracted considerable attention owing to its solvent-free operation, scalability, and compatibility with Quality-by-Design principles and continuous pharmaceutical manufacturing [18,19,20,21]. During HME, crystalline API particles are incorporated into a softened polymeric carrier, resulting in amorphization through mechanisms that depend on both the physicochemical properties of the formulation and the selected processing conditions [18, 21, 22]. Two principal amorphization pathways can be distinguished. For APIs with melting temperatures below the processing temperature, amorphization is predominantly achieved by melting of the crystalline drug followed by mixing with the polymer melt [18]. Conversely, high-melting-point APIs often remain crystalline throughout processing and become amorphous only through progressive dissolution in the softened polymer [23, 24]. Taylor and co-workers extensively investigated this particle-mediated amorphization mechanism and demonstrated that the incorporation of crystalline drug particles into softened polymers is governed by the interplay between drug-polymer miscibility and the kinetics of particle dissolution under extrusion-relevant conditions [24,25,26]. This pathway is inherently more challenging because complete dissolution of crystalline particles must be achieved within the relatively short residence time of the extrusion process while avoiding thermal degradation of both formulation components [22, 27,28,29].
Incomplete dissolution of API particles in the polymer melt may result in residual crystallinity in the final ASD, which can compromise product performance and physical stability [8, 30]. Consequently, understanding the factors governing the incorporation of crystalline particles into softened polymers is essential for formulation development. This process is governed by the interplay between thermodynamic and kinetic factors [25]. Thermodynamic aspects determine whether the dissolution of the API within the polymer matrix is energetically feasible under the selected processing conditions and define the equilibrium phase behaviour of the system [25]. Taylor and co-workers extensively investigated the thermodynamic behaviour of drug-polymer systems and demonstrated that drug-polymer miscibility and equilibrium solubility constitute the thermodynamic driving force governing ASD formation [25, 31]. Extensive research has focused on predicting drug-polymer miscibility using approaches such as phase diagrams, melting point depression, and Flory–Huggins interaction parameters [6, 25, 31,32,33]. Collectively, these approaches provide a framework for selecting formulation compositions and processing temperatures that are thermodynamically feasible for ASD formation [25, 33].
However, thermodynamic feasibility alone does not ensure successful amorphization during HME [25]. Even in thermodynamically favourable systems, the available processing time may be insufficient for complete dissolution of crystalline particles in the polymer melt [23]. The rate of this process is governed by several kinetic factors, most notably particle size, diffusion distance, polymer melt viscosity, processing temperature, and residence time [22, 25, 26]. Li et al. demonstrated that particle size represents one of the key material attributes governing the rate of API dissolution in polymer melts during HME, with smaller particles exhibiting accelerated amorphization owing to their larger specific surface area and shorter diffusion pathways [22]. Accordingly, this material attribute has repeatedly been identified as one of the key determinants of amorphization kinetics during HME [22, 24].
Subsequent studies further demonstrated that particle engineering strategies can significantly influence drug incorporation and the extent of residual crystallinity in the final ASD [24, 26]. More recently, Taylor and co-workers systematically investigated particle-size-dependent amorphization kinetics and highlighted the interplay between diffusion-controlled particle dissolution, drug-polymer miscibility, and process conditions in determining the extent of amorphization achieved during HME [24, 26]. Despite these advances, current knowledge has been derived predominantly from extrusion experiments. Such studies are inherently time-consuming, require relatively large quantities of material, and typically evaluate the final ASD rather than the particle incorporation process itself [19, 34]. Moreover, they provide only indirect information regarding particle dissolution kinetics because amorphization is generally assessed after processing using bulk analytical techniques [6, 35]. Consequently, rapid experimental approaches capable of directly monitoring the behaviour of individual API particles before extrusion remain limited, motivating the development of complementary preformulation screening methodologies [19, 34, 36,37,38].
Several analytical techniques have been employed to investigate drug-polymer systems during formulation development, including differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Raman spectroscopy, optical microscopy, and even inverse gas chromatography (IGC) [34, 39,40,41,42,43]. Thermal and diffraction techniques provide valuable information regarding crystallinity, thermal transitions, and phase behaviour but primarily characterize the bulk properties of the formulation [25, 35]. Moreover, preparing separate narrow particle-size fractions for DSC analysis may alter the original particle characteristics, including their surface properties, and may therefore not fully represent the particle-size distribution of the starting API material. In contrast, hot-stage microscopy (HSM) enables direct visualization of individual crystalline particles during heating and therefore provides unique spatially resolved information regarding their behaviour within a softened polymer [34, 44, 45]. Previous studies by Zečević, Agrawal and others demonstrated the applicability of HSM for investigating drug-polymer interactions, estimating suitable processing temperatures and qualitatively monitoring the progressive disappearance of crystalline particles during heating [34, 36]. More recently, Taylor’s group emphasized the importance of combining microscopic observations with complementary analytical techniques to better understand drug incorporation during thermal processing [25]. Nevertheless, HSM has primarily served as a qualitative visualization tool, and previous HSM studies have predominantly used particle disappearance as a qualitative indicator of drug-polymer interaction and processing suitability. To our knowledge, a standardized workflow enabling particle-size-resolved quantification of dissolution extent and the derivation of formulation-specific particle-size criteria from HSM data has not been reported.
The present work addresses this knowledge gap by focusing on the kinetic aspects of API particle dissolution in softened polymer matrices. Rather than investigating equilibrium drug-polymer miscibility or predicting thermodynamically feasible processing conditions, this study evaluates how API particle size influences the rate and extent of particle dissolution under predefined thermal conditions. While hot-stage microscopy has previously been employed as a qualitative tool for observing drug-polymer interactions and crystal disappearance during heating, its potential for systematic quantitative assessment of particle dissolution behaviour has received considerably less attention. Using a model high-melting-point API-polymer system as a case study, the proposed methodology was used to identify particle-size ranges associated with complete or incomplete dissolution under the selected experimental conditions. Rather than replacing extrusion experiments or comprehensive solid-state characterization, it is designed to complement existing development workflows by enabling early assessment of particle-size-related risks associated with incomplete drug dissolution in softened polymer matrices.
Download the full article as PDF here Hot-Stage Microscopy as a Quantitative Preformulation Tool for Assessing API Particle Dissolution in Molten Polymer Matrices
or continue reading here
Materials
The investigated compound (API), kindly provided by Zentiva, k.s. (Czech Republic), is a low-molecular-weight drug substance with low aqueous solubility and moderate lipophilicity. It can be classified as a Biopharmaceutics Classification System (BCS) class II compound, exhibiting low solubility and high permeability. More specifically, according to the Developability Classification System (DCS), it falls into class IIb due to its solubility-limited absorption. The compound is neutral or only weakly ionizable within the physiological pH range and demonstrates limited solubility across a broad pH spectrum. It is a crystalline solid with a relatively high melting point (> 220°C), which contributes to its dissolution-limited behaviour in the softened polymer. The compound is predominantly manufactured and handled as a single crystalline form and is not typically known as a polymorphically rich API. The oral absorption of API may be influenced by food intake, with administration under fed conditions potentially enhancing its bioavailability, likely due to improved solubilization in the gastrointestinal tract. Pharmacokinetically, API exhibits dose-dependent exposure with moderate to high permeability and absorption.
The second solid component was Kollidon® VA 64 (K64) (BASF Pharma, Germany), a pharmaceutical copovidone widely used as a carrier polymer for amorphous solid dispersions owing to its favourable thermomechanical properties, drug-polymer miscibility and crystallization-inhibiting capability. K64 is widely utilised in hot-melt extrusion (HME) due to its optimal glass transition temperature (101–108°C), which ensures suitable melt viscosity under typical processing conditions. Furthermore, its high thermal stability prevents degradation at elevated temperatures well exceeding 200°C, which is essential for processing high-melting-point APIs.
Liquid nitrogen (SIAD Czech Spol. s.r.o., Czech Republic) was also used as a cooling medium for the HSM, and gaseous nitrogen as an atmosphere during DSC measurements. Tween® 80 (Sigma-Aldrich, Czech Republic) and demineralized water were used for the preparation of the dispersion medium for PSD measurements of pure API.
Novák, D., Römerová, S., Krejčík, L. et al. Hot-Stage Microscopy as a Quantitative Preformulation Tool for Assessing API Particle Dissolution in Molten Polymer Matrices. AAPS PharmSciTech 27, 334 (2026). https://doi.org/10.1208/s12249-026-03586-1
Are you looking for excipients in commercial quantities?












































All4Nutra







